SIEN - Sientra, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.00
-0.20 (-1.52%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.20
Open13.23
Bid12.25 x 800
Ask23.22 x 800
Day's Range12.93 - 13.46
52 Week Range8.79 - 26.79
Volume370,412
Avg. Volume394,519
Market Cap371.791M
Beta (3Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.86
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Sientra Announces Preliminary Unaudited Fourth Quarter 2018 Net Sales and Appointment of Aesthetic Industry Veteran to Board of Directors

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced preliminary unaudited nets sales for the fourth quarter 2018. In addition, as previously disclosed, the Board of Directors of Sientra appointed Mary M. Fisher as a director of the Company effective January 1, 2019.

  • Is Sientra Inc (SIEN) A Good Stock To Buy?
    Insider Monkey27 days ago

    Is Sientra Inc (SIEN) A Good Stock To Buy?

    “October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Simply Wall St.last month

    How Much Did Sientra, Inc.’s (NASDAQ:SIEN) CEO Pocket Last Year?

    In 2015 Jeff Nugent was appointed CEO of Sientra, Inc. (NASDAQ:SIEN). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look Read More...

  • GlobeNewswirelast month

    Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sientra, Inc. (SIEN) (“Sientra” or the “Company”), a medical aesthetics company, today announced that on December 5, 2018, the Compensation Committee of the Board of Directors approved equity award grants under the Sientra Inc. Inducement Plan to 31 new employees, including to 22 new employees at the Company’s miraDry subsidiary. The new employees were granted restricted stock units representing a total of 62,209 shares of common stock. The restricted stock units will vest in three equal annual installments.  In each case, the vesting of shares is contingent upon the recipient’s continued service with the Company through each vesting date.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Implied Volatility Surging for Sientra (SIEN) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Sientra (SIEN) Stock Options

    Investors need to pay close attention to Sientra (SIEN) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SIEN earnings conference call or presentation 6-Nov-18 9:30pm GMT

    Q3 2018 Sientra Inc Earnings Call

  • Sientra (SIEN) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Sientra (SIEN) Reports Q3 Loss, Tops Revenue Estimates

    Sientra (SIEN) delivered earnings and revenue surprises of -7.46% and 3.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Sientra: 3Q Earnings Snapshot

    The Santa Barbara, California-based company said it had a loss of 72 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Sientra Reports Third Quarter 2018 Financial Results

    Achieves Total Net Sales of $16.9 Million, Pro Forma Growth of 58% YoY, 72% on a GAAP Basis Record miraDry Net Sales of $8.3 Million, Pro Forma Growth of 174% YoY, 282% on a.

  • GlobeNewswire3 months ago

    Sientra to Participate in Upcoming Investor Conferences

    SANTA BARBARA, Calif., Oct. 31, 2018 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, announced today that members of management are scheduled to participate in.

  • GlobeNewswire3 months ago

    Sientra® to Release Third Quarter 2018 Financial Results on November 6, 2018

    SANTA BARBARA, Calif., Oct. 23, 2018 -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release.

  • PR Newswire3 months ago

    Sientra Announces FULL CIRCLE Grant Recipients

    Eight Breast Cancer Nonprofits across the U.S. Selected to Receive Funding SANTA BARBARA, Calif. , Oct. 23, 2018 /PRNewswire/ -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, today announced ...

  • Are Options Traders Betting on a Big Move in Sientra (SIEN) Stock?
    Zacks3 months ago

    Are Options Traders Betting on a Big Move in Sientra (SIEN) Stock?

    Investors need to pay close attention to Sientra (SIEN) stock based on the movements in the options market lately.

  • SEC sues U.S. breast-implant company's ex-CEO after stock dive
    Reuters4 months ago

    SEC sues U.S. breast-implant company's ex-CEO after stock dive

    Hani Zeini, 54, was accused of letting the offering close on Sept. 23, 2015, despite having learned three days earlier from the chief executive of the company's sole supplier that European implant sales would be suspended because contamination had been detected in an audit of manufacturing procedures. Sientra's share price sank 52.9 percent on Sept. 24, 2015, to $9.70 from $20.58, after it disclosed that the U.K. Medicines and Healthcare Products Regulatory Agency had suspended the certificate needed for the supplier, Brazil's Silimed, to sell the implants. The SEC said Zeini had hid "damaging" details from "every other professional" working on his Santa Barbara, California-based company's 3 million share offering, including its chief financial officer, directors, lawyers, auditors and bankers, and tried to cover his tracks after it was done.

  • Reuters4 months ago

    SEC sues ex-CEO of California breast implant company after stock nosedived

    The U.S. Securities and Exchange Commission on Wednesday sued the founder and former chief executive of Sientra Inc for fraudulently concealing problems with his company's breast and other implants as it was raising $61.4 million in a public stock offering. Hani Zeini was accused of letting the offering close on Sept. 23, 2015, despite having learned three days earlier from the chief executive of the company's sole supplier that European implant sales would be suspended because contamination had been detected in an audit of manufacturing procedures. Sientra's share price sank 52.9 percent on Sept. 24, 2015, to $9.70 from $20.58, after it disclosed that the U.K. Medicines and Healthcare Products Regulatory Agency had suspended the certificate needed for the supplier, Brazil's Silimed, to sell the implants.

  • PR Newswire5 months ago

    Sientra FULL CIRCLE™ Grant Applications Open to U.S. Breast Cancer Organizations

    SANTA BARBARA, Calif., Aug. 15, 2018 /PRNewswire/ -- Sientra, Inc. (SIEN), a medical aesthetics company, today announced that its FULL CIRCLE grant applications are now open for any U.S. based, nonprofit breast cancer organizations supporting breast cancer aid, research, patient outreach, advocacy, and prevention. The application period will end on September 15, 2018, and recipients will be announced by Sientra in October 2018. Sientra FULL CIRCLE™ is a first-of its-kind charitable program aimed at aiding nonprofits in the breast cancer community who are committed to making a meaningful difference.

  • Associated Press5 months ago

    Sientra: 2Q Earnings Snapshot

    The Santa Barbara, California-based company said it had a loss of 73 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • ACCESSWIRE5 months ago

    Sientra, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Sientra, Inc. (NASDAQ: SIEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • PR Newswire6 months ago

    Sientra to Launch State-of-the-Art Innovation Facility

    SANTA BARBARA, Calif., July 31, 2018 /PRNewswire/ -- Sientra, Inc. (SIEN), a medical aesthetics company, today announced its investment in opening a new state-of-the-art Sientra Lab and Innovation Center of Excellence (SLICE) near its corporate headquarters in Santa Barbara, CA. The new development lab facility will enable Sientra to accelerate its efforts on key portfolio additions and enhancements.